Get this report today!
Table of Contents
Multiple Sclerosis - Pipeline Review, H2 2011
Global Markets Direct’s, 'Multiple Sclerosis - Pipeline Review, H2 2011', provides an overview of the Multiple Sclerosis therapeutic pipeline. This report provides information on the therapeutic development for Multiple Sclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Multiple Sclerosis. 'Multiple Sclerosis - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Multiple Sclerosis.
- A review of the Multiple Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Multiple Sclerosis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Multiple Sclerosis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Talk to Shadi
+1 (805) 652 26 26
The Largest Collection of Market Research Reports
From +200,000 authoritative sources
PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022 Summary The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use ...
Product Synopsis Disease-related, demographic, and desire-led drivers are making health of growing importance to food marketers. However, barriers such as cost, habits, and confusion over how to eat healthily ...
REPORT HIGHLIGHTS The global digital pathology market totaled nearly $2.1 billion in 2012. This market is expected to grow at a compound annual growth rate (CAGR) of 14.7% from $2.2 billion in 2013 to ...
... liver biopsy (currently only definitive test to confirm nash diagnosis and stage disease) simple steatosis nash liver prognosis good treat cardiac risks treat associated conditions pcps ...
... New congenital heart disease review what matters a commitment to research ensures that services are continually focussed on improvement and development, so networks will be required to have ...
... Claimed for critical illnesses and attacks without chest pain are a real occurrence stroke - friends life have removed the exclusion for a stroke due to traumatic injury to brain tissue or blood vessels ...
Reportlinker.com © Copyright 2014. All rights reserved.